← Back
Data updated: Mar 29, 2026
JUBILANT CADISTA
NeurologyCardiovascularGastroenterology
Generics
JUBILANT CADISTA is a generic drug manufacturer focused on Neurology, Cardiovascular, Gastroenterology.
1988
Since
25
Drugs
-
Trials
334
Approved (2yr)
Key Drugs
No active drugs
Top Drug Revenues Pro
Loading...
Revenue Over Time Pro
Loading...
Recent Activity
MYCOPHENOLATE MOFETIL 2026-02-23
Labeling
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE 2026-02-17
Labeling
ALENDRONATE SODIUM 2026-02-03
Labeling
ALENDRONATE SODIUM 2026-02-03
Labeling
LAMOTRIGINE 2026-01-30
Labeling
LAMOTRIGINE 2026-01-30
Labeling
LAMOTRIGINE 2026-01-30
Labeling
LAMOTRIGINE 2026-01-30
Labeling
SEC Filings
Pro
Loading...
Therapeutic Areas
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Neurology 27%
3 drugs
Cardiovascular 18%
2 drugs
Gastroenterology 18%
2 drugs
Dermatology 18%
2 drugs
Infectious Disease 18%
2 drugs
Pipeline Forecast
Loading...
Loading...
Upcoming Trial Milestones Pro
Loading...
Patent Cliff Pro
Loading...
Loading...
Loading...
Competitors by Therapeutic Area
Pfizer big-pharma
Infectious Disease, Dermatology, Gastroenterology
APOTHECON specialty
Infectious Disease, Dermatology, Cardiovascular, Gastroenterology
Baxter specialty
Infectious Disease, Cardiovascular, Dermatology
LEDERLE big-pharma
Infectious Disease, Cardiovascular, Neurology, Dermatology
PAI HOLDINGS PHARM big-pharma
Dermatology, Infectious Disease, Neurology, Cardiovascular
Active (15)
DROXIDOPA LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE DROSPIRENONE AND ETHINYL ESTRADIOL ALENDRONATE SODIUM OXCARBAZEPINE LAMOTRIGINE CLARITHROMYCIN METHENAMINE HIPPURATE PROCOMP CLOMIPRAMINE HYDROCHLORIDE LOPERAMIDE HYDROCHLORIDE CARBAMAZEPINE HYDROCHLOROTHIAZIDE DOXEPIN HYDROCHLORIDE SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Discontinued (10)
Company Info
- First Approval
- 1988-02-01
- Latest
- 2025-01-22
- Applications
- 29